Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wellcome Trust’s Syncona Bets On Gene Therapy in Eye Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

The profit-oriented evergreen fund of Britain’s charitable foundation The Wellcome Trust, Syncona, has invested £12 million in an academic spin-out to develop and commercialize therapies for treating degenerative eye diseases.

You may also be interested in...

Start-Up Quarterly Statistics, Q1 2014

Start-up companies raised $1.18 billion during the first quarter of 2014, up $2.8 million from last quarter’s total. Cancer was the leading therapy area involved in alliances.

Abingworth Attracts $375M For Its New Bioventures Fund

The committed capital is nearly half what the 40-year-old firm raised from its previous vehicle and its sidecar in 2007–2008, but it's a huge sum compared with what most life science VCs can drum up these days.

Wellcome Trust Launches £200 million “Evergreen” Investment Fund

Britain’s charitable foundation The Wellcome Trust has formally launched a £200 million ($325 million) fund that will invest in both early and growth-stage companies, taking a long-term view and focused initially on opportunities in the UK, Europe and on the U.S East Coast.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts